DUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 ...
The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk ... like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable ...
Theravance Biopharma ( (TBPH) ) has released its Q3 earnings. Here is a breakdown of the information Theravance Biopharma presented to its ...
Healthcare Analysts discuss the recently-held AASLD Meeting (relevant companies ABUS HOOK BRNS VIR GSK (GSK) ALGS GILD) and catch-up on Chronic ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Teva Pharmaceutical Industries Ltd. ADR 1.52% $19.75B ...
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
That was the instant response of Emma Walmsley, CEO of GSK plc, reacting to breaking news from the U.S. that Donald Trump has won a second term in office.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback